An update on promising agents for the treatment of cancer cachexia

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 4, 2009, Pages 258-262

  Madeddu, Clelia ^a   Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cancer cachexia; Clinical trials; Combined approach; Emerging drugs; Proinflammatory cytokines

Indexed keywords

ANABOLIC AGENT;

ARTICLE; CACHEXIA; DRUG DESIGN; HUMAN; NEOPLASM;

ANABOLIC AGENTS; CACHEXIA; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 72449160114     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283311c6f     Document Type: Article

References (31)

1. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799. This study reports the updated definition of cachexia that emerged from an International Consensus Conference in 2008. The lack of a definition accepted by clinician and researchers has limited identification and treatment of cachectic patients as well as the development and approval of potential therapeutic agents. Therefore, this consensus operational definition provides an opportunity for increased research.
2. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 2008; 16:447-451.
3. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44:1124-1132. This study highlights the concept that multimodal management of cachexia can be the optimal approach. Moreover, it shows that there is an urgent need for further development of a formal definition of the cachexia spectrum and robust biomarkers of precachexia and patient-oriented outcomes for cachexia randomized intervention trials.
4. Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008; 6:18-25.
5. Lai V, George J, Richey L, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008; 30:67-74. This was the first pilot study which demonstrated effectiveness of COX-2 inhibitors in patient with cancer cachexia.
6. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98:300-308.
7. Garcia J. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol 2007; 25 (Suppl) [abstract 9133].
8. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008; 24:806-814. This review focuses on data regarding the efficacy of ghrelin agonists in treating cachexia caused by multiple underlying diseases and on potential issues to follow as more comprehensive studies are conducted. This review covers all the most emerging findings and concerns regarding the use of ghrelin mimetics in cachexia.
9. Lesser GJ, Case D, Ottery F, et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight(wt)and quality of life(QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol 2008; 26 (Suppl) [abstract 9513]. This abstract reports the effectiveness on primary key variables of CACS (i.e. LBM and quality of life) of a combined approach consisting of progestagens and oxandrolone.
10. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009; 12:232-240. This review is focused on the rationale for SARM development, the molecular basis of androgen action, the mechanistic basis of tissue selectivity, and potential clinical applications for SARMs. The study gives a complete up-to-date analysis of these promising agents.
11. Evans W, Smith M, Morley J, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: implications for cancer cachexia patients. J Clin Oncol 2007; 25 (Suppl) [abstract 9119].
12. Morton RAJ, Barnette KG, Hancock ML, et al. The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia. Ann Meeting Endocrinol Soc 2009:S21. This study reports the first large randomized trial carried out in cachectic cancer patients which demonstrated the clinical efficacy of a compound of the new class of SARMs. The findings are of relevance both in terms of amelioration of key primary endpoints of CACS (LBM and. physical function) and selection of up-todate methods of evaluation.
13. Braiteh F, Dalal S, Khuwaja A, et al. Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer. J Clin Oncol 2008; 26 (Suppl) [abstract 20529].
14. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate. J Clin Oncol 2008; 26 (Suppl) [abstract 9576].
15. Clarke SJ, Smith JT, Gebbie C, et al. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancerhumanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 2009; 27: (Suppl) [abstr 3025]. The study reports the preliminary efficacy data on the use of an anti-IL-6 antibody in a population of advanced cancer patients. The results suggested a potential efficacy of this drug, which has a strong rationale and is expected to play such a crucial role in the treatment of CACS.
16. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008; 88:729-767.
17. Kenley RA, Denissenko MF, Mullin RJ, et al. Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia. Oncol Rep 2008; 19:1113-1121.
18. Taylor LA, Pletschen L, Arends J, et al. Marine phospholipids - a promising new dietary approach to tumor-associated weight loss. Support Care Cancer 2009 Apr 29 [Epub ahead of print].
19. Liu Y, Jia Z, Dong L, et al. A randomized pilot study of atractylenolide I on gastric cancer cachexia patients. Evid Based Complement Alternat Med 2008; 5:337-344.
20. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89:381- 410. This is the most in-depth and updated review of the pathophysiology of CACS. Knowledge of the mechanisms of tissue destruction in cachexia should improve methods of treatment.
21. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008; 13:73-78. The present article reviews the recent therapeutic approaches that have been designed to fight and counteract muscle wasting in different pathological states such as cancer, AIDS and chronic heart failure.
22. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008; 24:305-313. This study reports the preliminary data on a very interesting randomized clinical trial aiming to identify the most effective treatment of CACS among five different up-todate treatment approaches.
23. Jatoi A.Weight loss in patients with advanced cancer: effects, causes, and potential management. Curr Opin Support Palliat Care 2008; 2:45-48. This review provides an update of the main interesting observations that have challenged our understanding of and approach to treating cancer-associated weight loss in patients with advanced, incurable malignancies.
24. Bossola M, Pacelli F, Tortorelli A, et al. Skeletal muscle in cancer cachexia: the ideal target of drug therapy. Curr Cancer Drug Targets 2008; 8:285-298. This review is focused on the therapeutic approach of cachexia addressing the skeletal muscle, as a potential target of therapy. The study gives a full update on the emerging, recently discovered drugs capable to inhibit the catabolic processes and to stimulate the anabolic pathways.
25. Russell ST, Siren PM, Siren MJ, et al. Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1, 2, 6-triphosphate. Cancer Chemother Pharmacol 2009; 64:517-527.
26. Deboer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 2006; 17:199-204.
27. Weyermann P, Dallmann R, Magyar J, et al. Orally available selective melanocortin- 4 receptor antagonists stimulate food intake and reduce cancerinduced cachexia in mice. PLoS One 2009; 4:e4774.
28. Wang Z, Zhao C, Moya R, et al. A novel role for CD4+T cells in the control of cachexia. J Immunol 2008; 181:4676-4684.
29. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007; 407:113-120.
30. van Norren K, Kegler D, Argiles JM, et al. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009; 100:713-722.
31. Tan BH, Deans DA, Skipworth RJ, et al. Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer 2008; 16:229-234.